EyePoint Pharmaceuticals to Host Investor Day on July 18, 2022
July 11 2022 - 7:30AM
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical
company committed to developing and commercializing therapeutics to
improve the lives of patients with serious eye disorders, today
announced it will host an Investor Day that will be held on Monday,
July 18, 2022 from 8:00 a.m. to 11:00 a.m. ET.
The Investor Day will feature commentary from
EyePoint’s management team as well as key opinion leader guest
speakers Carl D. Regillo, M.D., FACS, Professor of Ophthalmology,
Thomas Jefferson University and Charles C. Wykoff, M.D., Ph.D.,
Director of Research, Retina Consultants of Texas. The agenda
includes a discussion on the science behind EyePoint's Durasert®
drug delivery platform, Phase 2 plans for EYP-1901, an
investigational sustained delivery anti-VEGF treatment initially
targeting wet AMD and a financial update.
A webcast and subsequent archived replay of the
presentation may be accessed via the Investors section of the
Company website at www.eyepointpharma.com. The replay will be
available for 90 days after the event.
About EyePoint
Pharmaceuticals
EyePoint Pharmaceuticals (Nasdaq: EYPT) is a
pharmaceutical company committed to developing and commercializing
therapeutics to help improve the lives of patients with serious eye
disorders. The Company's pipeline leverages its proprietary
Durasert® technology for sustained intraocular drug delivery
including EYP-1901, an investigational sustained delivery
intravitreal anti-VEGF treatment initially targeting wet
age-related macular degeneration. The proven Durasert drug delivery
platform has been safely administered to thousands of patients'
eyes across four U.S. FDA approved products, including YUTIQ® for
the treatment of chronic non-infectious uveitis affecting the
posterior segment of the eye, which is currently marketed by the
Company. EyePoint Pharmaceuticals is headquartered in Watertown,
Massachusetts.
Investors:
Christina TartagliaStern IRDirect:
212-698-8700christina.tartaglia@sternir.com
Media Contact
Amy PhillipsGreen Room CommunicationsDirect:
412-327-9499aphillips@greenroompr.com
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Historical Stock Chart
From Apr 2023 to Apr 2024